Moreover, it was determined that chronic pharmacological intervention with sEH inhibitors reduced myocardial hypertrophy and fibrosis development and progression, decreased inflammation and improved heart function post-myocardial infarction (MI) [8–11]. Here, EPHX2 is linked to cardiac hypertrophy.